Use of Canephron® N in treatment of acute uncomplicated cystitis in women
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Patients and methods. In our work was attended by 22 women with a diagnosis of acute uncomplicated cystitis. The mean age was 29,0±1,8 years (from 19 to 51 years. The criteria of effectiveness were changes in symptoms and laboratory parameters according to the urinary tests at Canephron® N monotherapy.
Results. After treating by Canephron® N there were observed significant improvement in symptoms of acute cystitis. Before treatment the average symptom score was 8,05±0,7 points, on the 3rd day of treatment it significantly decreased to 5,1±1,0 points (p<0,05) on day 7 of treatment it was up to 2,9±1,0 points, in the phase of observation of 37 days after initiation of therapy by Canephron® N othe average score of symptoms was 0,1±0,3 points. Frequency leukocyturia on the 7 day of treatment according to a study by urine microscopy was 83,3%, and by the 37 th day after the start of Canephron® N (phase monitoring) significantly decreased to 37,5% (p<0,05). Canephron® N showed statistically significant antibacterial activity in acute cystitis. Prior to initiating therapy the growth of microorganisms at a titer of more than 100 000 units was detected in 72,7% of patients after 2 weeks of treatment (on day 37 of observation) – in 28,6% of patients (p<0,05).
Conclusions. Our results suggest that Canephron® N can be an effective and well-tolerated alternative treatment of uncomplicated infections of the lower urinary tract in women, allowing to reduce the use of antibiotics. Appointment of the drug as a monotherapy Canephron® N acute cystitis and duration of treatment requires further study and discussion.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Little P, Moore MV, Turner S, et al. Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. BMJ. 2010;340:199-204. doi: 10.1136/bmj.c199.
Ivanov D, Abramov-Sommariva D, Moritz К, et al. An open label, non-controlled, multicentre, interventional trial to investigate the safety and efficacy of Canephron® N in the managementof uncomplicated urinary tract infections (uUTIs). Clinical Phytoscience. 2015;1(7):1-11. doi: 10.1186/s40816-015-0008-x.
Wagenlehner FM, Weidner W, Naber KG. An update on uncomplicated urinary tract infections in women. Current Opinion in Urology. 2009;19:368-374. doi: 10.1097/mou.0b013e32832ae18c.
Ferry SA, Holm SE, Stenlund H, et al. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand J Inf Dis. 2004;36:296-301. doi: 10.1080/00365540410019642.
Naber KG. Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in eastern europe and central asia. Research and reports in Urology. 2013;5:39-46. doi: 10.2147/rru.s39288.
